Valuation: Jazz Pharmaceuticals plc

Market Cap 14.43B 12.65B 11.66B 10.92B 20.48B 1,361B 20.9B 140B 54.25B 673B 54.19B 53.01B 2,333B P/E 2026 *
16.4x
P/E 2027 * 14.8x
Enterprise Value 16.13B 14.14B 13.04B 12.21B 22.89B 1,522B 23.36B 157B 60.63B 752B 60.57B 59.25B 2,608B EV / Sales 2026 *
3.57x
EV / Sales 2027 * 2.99x
Free-Float
96.61%
Yield 2026 *
-
Yield 2027 * -
1 day+1.69%
1 week+2.39%
Current month-2.74%
1 month-3.17%
3 months+25.91%
6 months+34.92%
Current year+35.31%
1 week 222.93
Extreme 222.93
234.08
1 month 220.74
Extreme 220.74
241.99
Current year 156.95
Extreme 156.95
243.32
1 year 105
Extreme 105
243.32
3 years 95.49
Extreme 95.49
243.32
5 years 95.49
Extreme 95.49
243.32
10 years 86.88
Extreme 86.88
243.32
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 61 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2019-10-24
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
Jun. 14Sell

Director

-1,157 0.0018%
Jun. 09Sell

General Counsel

-1,200 0.0019%
Jun. 02Don

Chief Executive Officer

-600 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+2.39%+115.17%+86.48% 14.43B
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.56%+7.44%+39.41%+57.74% 363.05B
Weighted average by Cap. +3.84%+8.90%+42.05%+80.19%

Financials

2026 *2027 *
Net sales 4.51B 3.96B 3.65B 3.42B 6.41B 426B 6.54B 43.86B 16.97B 210B 16.95B 16.58B 730B 4.84B 4.24B 3.91B 3.66B 6.87B 456B 7.01B 47.01B 18.19B 226B 18.17B 17.77B 782B
Net income 961M 843M 777M 727M 1.36B 90.65B 1.39B 9.33B 3.61B 44.8B 3.61B 3.53B 155B 1.05B 918M 846M 792M 1.49B 98.79B 1.52B 10.17B 3.94B 48.83B 3.93B 3.85B 169B
Net Debt 1.7B 1.49B 1.37B 1.28B 2.41B 160B 2.46B 16.5B 6.38B 79.17B 6.38B 6.24B 275B 15.43M 13.53M 12.47M 11.67M 21.89M 1.46B 22.35M 150M 57.99M 719M 57.93M 56.67M 2.49B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-06-26 $230.02 +1.69% 845,914
26-06-25 $226.20 -1.59% 680,207
26-06-24 $229.85 -0.17% 719,880
26-06-23 $230.25 +1.92% 862,820
26-06-22 $225.92 +0.56% 979,965
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
230.02USD
Average target price
257.00USD
Spread / Average Target
+11.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock